Planned versus attained design in phase II clinical trials.
The standard phase II trial problem is to decide whether or not to continue the testing of a new agent (or combination). Typically, one tests the null hypothesis HO: p = pO against the alternative HA: p = pA, where p is the probability of response. There is available a variety of two-stage phase II designs, including optimal designs according to various criteria. Practical considerations in the conduct of multicentre trials, however, make it difficult to follow designs precisely. We investigate several approaches to adapting stopping rules when the attained sample size is not the planned size. We find that a simple approach of testing HA: p = pA at the 0.02 level at the first stage and HO: p = pO at the 0.055 level at the second stage works well across a variety of powers, pOs and pAs.
Green
S J
SJ
Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.
Dahlberg
S
S
D003657:Decision Making; D004341:Drug Evaluation / Q000379:methods / Q000592:standards*; D006801:Humans; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy; D010934:Planning Techniques; D011336:Probability; D012107:Research Design / Q000592:standards*; D012494:Sampling Studies